NO20004799L - Anvendelse av cabergolin ved behandling av urolig bensyndrom - Google Patents

Anvendelse av cabergolin ved behandling av urolig bensyndrom

Info

Publication number
NO20004799L
NO20004799L NO20004799A NO20004799A NO20004799L NO 20004799 L NO20004799 L NO 20004799L NO 20004799 A NO20004799 A NO 20004799A NO 20004799 A NO20004799 A NO 20004799A NO 20004799 L NO20004799 L NO 20004799L
Authority
NO
Norway
Prior art keywords
cabergoline
treatment
troubled
leg syndrome
syndrome
Prior art date
Application number
NO20004799A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004799D0 (no
Inventor
Peter Schueler
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20004799D0 publication Critical patent/NO20004799D0/no
Publication of NO20004799L publication Critical patent/NO20004799L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20004799A 1998-03-27 2000-09-26 Anvendelse av cabergolin ved behandling av urolig bensyndrom NO20004799L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7963998P 1998-03-27 1998-03-27
PCT/US1999/004269 WO1999048484A2 (en) 1998-03-27 1999-03-24 Use of cabergoline in the treatment of restless legs syndrome

Publications (2)

Publication Number Publication Date
NO20004799D0 NO20004799D0 (no) 2000-09-26
NO20004799L true NO20004799L (no) 2000-10-11

Family

ID=22151836

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004799A NO20004799L (no) 1998-03-27 2000-09-26 Anvendelse av cabergolin ved behandling av urolig bensyndrom

Country Status (23)

Country Link
US (1) US6114326A (cs)
EP (1) EP1066038B1 (cs)
JP (1) JP2002507562A (cs)
KR (1) KR100597517B1 (cs)
CN (1) CN1303286A (cs)
AT (1) ATE313326T1 (cs)
AU (1) AU747751B2 (cs)
BR (1) BR9908953A (cs)
CA (1) CA2320204A1 (cs)
CZ (1) CZ297284B6 (cs)
DE (1) DE69929041T2 (cs)
DK (1) DK1066038T3 (cs)
EA (1) EA002554B1 (cs)
ES (1) ES2255255T3 (cs)
HU (1) HUP0101954A3 (cs)
IL (1) IL138522A0 (cs)
NO (1) NO20004799L (cs)
NZ (1) NZ507176A (cs)
PL (1) PL343593A1 (cs)
SK (1) SK13312000A3 (cs)
TR (1) TR200002759T2 (cs)
WO (1) WO1999048484A2 (cs)
ZA (1) ZA200004452B (cs)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
NZ505193A (en) 1997-12-22 2003-03-28 Euro Celtique S Opioid agonist/antagonist combinations
US6477408B1 (en) * 2000-03-07 2002-11-05 Northwestern University Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
US6426713B1 (en) * 2000-07-05 2002-07-30 Cirrus Logic, Inc. Independent control of calibration registers in a multi channel A-D converter
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020123503A1 (en) * 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
ATE424205T1 (de) 2001-03-30 2009-03-15 Toray Industries Mittel zur behandlung des syndroms der unruhigen beine
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US20030134844A1 (en) * 2001-10-31 2003-07-17 Pfizer Inc. Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
US20030176822A1 (en) * 2002-03-12 2003-09-18 Morgenlander Joel C. Method of treating restless leg syndrome
JP4755810B2 (ja) 2002-04-05 2011-08-24 ユーロ−セルティーク エス.エイ. オキシコドン及びナロキソンを含有する医薬製剤
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
ES2310258T5 (es) 2002-08-30 2012-05-31 Kyowa Hakko Kogyo Co., Ltd. Antagonistas de los receptores de adenosina A2A para tratar el síndrome de piernas inquietas o mioclono nocturno
SG146643A1 (en) 2003-09-17 2008-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
KR20060030175A (ko) * 2004-10-05 2006-04-10 경북대학교 산학협력단 무정위성 운동 치료용 약학조성물
CN101132772B (zh) * 2005-01-28 2012-05-09 欧洲凯尔特公司 耐醇剂型
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
ES2684821T3 (es) * 2005-12-29 2018-10-04 Lexicon Pharmaceuticals, Inc. Derivados de aminoácidos multicíclicos y métodos de su uso
EP2007369A4 (en) * 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
WO2008046149A1 (en) * 2006-10-17 2008-04-24 Biologic Health Solutions Pty Ltd Herbal compositions for the prevention or treatment of restless leg syndrome
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US7939665B2 (en) 2007-05-04 2011-05-10 Apotex Pharmachem Inc. Efficient process for the preparation of cabergoline and its intermediates
EP2067780A1 (en) * 2007-12-07 2009-06-10 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
KR20140141727A (ko) 2009-03-10 2014-12-10 유로-셀티큐 에스.에이. 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
PT2413912T (pt) 2009-04-01 2019-06-11 Bial Portela & Ca Sa Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir
US8690933B2 (en) * 2009-08-31 2014-04-08 Brigham Young University System and method for treating symptoms of restless legs syndrome
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
PL232974B1 (pl) * 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń
WO2021067751A1 (en) 2019-10-03 2021-04-08 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome
JP7159169B2 (ja) 2017-01-05 2022-10-24 ノクトリックス ヘルス インコーポレイテッド レストレスレッグス症候群または過活動神経治療
AU2020358093A1 (en) 2019-10-03 2022-04-28 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders

Also Published As

Publication number Publication date
WO1999048484A3 (en) 1999-11-25
US6114326A (en) 2000-09-05
HUP0101954A2 (hu) 2001-12-28
EA200000994A1 (ru) 2001-02-26
DE69929041D1 (de) 2006-01-26
WO1999048484A2 (en) 1999-09-30
BR9908953A (pt) 2000-12-05
JP2002507562A (ja) 2002-03-12
EP1066038A2 (en) 2001-01-10
TR200002759T2 (tr) 2001-02-21
KR100597517B1 (ko) 2006-07-10
EA002554B1 (ru) 2002-06-27
SK13312000A3 (sk) 2001-05-10
EP1066038B1 (en) 2005-12-21
DE69929041T2 (de) 2006-07-20
NZ507176A (en) 2003-09-26
PL343593A1 (en) 2001-08-27
CZ297284B6 (cs) 2006-10-11
HUP0101954A3 (en) 2002-09-30
DK1066038T3 (da) 2006-04-24
CZ20003419A3 (cs) 2002-01-16
AU747751B2 (en) 2002-05-23
ZA200004452B (en) 2002-02-27
KR20010052222A (ko) 2001-06-25
ES2255255T3 (es) 2006-06-16
IL138522A0 (en) 2001-10-31
CA2320204A1 (en) 1999-09-30
CN1303286A (zh) 2001-07-11
AU3353199A (en) 1999-10-18
ATE313326T1 (de) 2006-01-15
NO20004799D0 (no) 2000-09-26

Similar Documents

Publication Publication Date Title
NO20004799D0 (no) Anvendelse av cabergolin ved behandling av urolig bensyndrom
MXPA03003912A (es) Tratamientos nuevos para el sindrome de piernas inquietas.
ATE424413T1 (de) Analoge des glucagon-ähnlichen peptids-1
DE60005810D1 (de) Fussstütze und möbelstück
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
IS5280A (is) Samsetningar til meðhöndlunar og fyrirbyggingar ásegamyndun í slagæð og notkun á þætti Xa lata einum sér og/eða í samsetningu með miðli gegn blóðflöguþyrpingu
NO20031860D0 (no) Kahalaolid F
NO993360L (no) Anvendelse av pramipeksol ved behandling av "restless leg"- syndromet
AU3922900A (en) Use of (valeriana) for the treatment of restless leg syndrome and related disorders
SE0302361D0 (sv) Inhibering av upptagning av monoamin
NO20005548D0 (no) Mykobakterieinhibitorer
GEP20074097B (en) Use of specific dose of fondaparinux sodium for the treatment of acs
NO20010786L (no) TPL-2/COT kinase og fremgangsmåter for anvendelse
DE50009728D1 (de) Mopwaschmittel
NO964545A (no) Protese omfattende leggdel, kalsojdel og fotdel
MXPA01010449A (es) Composicion y metodo util para el tratamiento del colico.
IT1309840B1 (it) Accessorio per il sostegno di calzini, gambaletti, calze e manufattianaloghi anche se privi di elastico.
ITPI990011U1 (it) Accessorio per il sostegno di calzini, gambaletti, calze e manufattianaloghi anche se privi di elastico.
KR980000461U (ko) 탁자다리
ITPD990199A1 (it) Tavolo da gioco e procedimento di gioco preferito
ITTS980017V0 (it) Sedia monogamba
DK199900219U3 (da) Kiropraktisk behandlings- og sidelejebehandlingsbord
MX9101325A (es) Composicion para regeneracion celular para el tratamiento de quemaduras con accion desinflamatoria
ES1037701Y (es) Sillon con reposapiernas extraible.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application